Biogen is handing over a staggering $350 million in cash for a partnership with Sangamo Therapeutics. The deal will leverage gene therapy to develop Alzheimer’s and Parkinson’s drugs.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more